Kenvue Inc. $KVUE Shares Sold by Truist Financial Corp

Truist Financial Corp cut its position in Kenvue Inc. (NYSE:KVUE) by 56.2% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 344,564 shares of the company’s stock after selling 441,892 shares during the period. Truist Financial Corp’s holdings in Kenvue were worth $5,592,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of the company. TrueMark Investments LLC lifted its stake in Kenvue by 8.8% during the 2nd quarter. TrueMark Investments LLC now owns 229,648 shares of the company’s stock valued at $4,807,000 after acquiring an additional 18,623 shares during the period. Vanguard Group Inc. raised its holdings in shares of Kenvue by 1.8% during the second quarter. Vanguard Group Inc. now owns 233,246,267 shares of the company’s stock worth $4,881,844,000 after purchasing an additional 4,101,880 shares during the last quarter. OFI Invest Asset Management lifted its position in Kenvue by 705.6% during the second quarter. OFI Invest Asset Management now owns 26,979 shares of the company’s stock valued at $565,000 after purchasing an additional 23,630 shares during the period. Simplicity Wealth LLC acquired a new stake in Kenvue during the 2nd quarter worth about $507,000. Finally, Aberdeen Group plc raised its stake in shares of Kenvue by 15.1% during the 2nd quarter. Aberdeen Group plc now owns 766,450 shares of the company’s stock valued at $16,015,000 after buying an additional 100,403 shares during the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Kenvue

In related news, Director Jeffrey C. Smith bought 3,200,000 shares of the business’s stock in a transaction dated Friday, December 12th. The stock was acquired at an average price of $17.37 per share, with a total value of $55,584,000.00. Following the completion of the purchase, the director directly owned 27,307,632 shares of the company’s stock, valued at approximately $474,333,567.84. This trade represents a 13.27% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. 0.17% of the stock is owned by corporate insiders.

Kenvue Stock Up 1.2%

Kenvue stock opened at $17.58 on Wednesday. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.98 and a quick ratio of 0.69. The stock has a market capitalization of $33.68 billion, a PE ratio of 23.44 and a beta of 0.59. The business has a 50 day simple moving average of $17.19 and a 200-day simple moving average of $17.93. Kenvue Inc. has a 12 month low of $14.02 and a 12 month high of $25.17.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Monday, November 3rd. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. The firm had revenue of $3.76 billion for the quarter, compared to analysts’ expectations of $3.83 billion. Kenvue had a net margin of 9.55% and a return on equity of 20.02%. The firm’s revenue for the quarter was down 3.5% compared to the same quarter last year. During the same quarter last year, the company earned $0.28 EPS. On average, analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, February 25th. Stockholders of record on Wednesday, February 11th will be given a $0.2075 dividend. The ex-dividend date is Wednesday, February 11th. This represents a $0.83 annualized dividend and a dividend yield of 4.7%. Kenvue’s dividend payout ratio (DPR) is 110.67%.

Wall Street Analysts Forecast Growth

Several analysts recently commented on KVUE shares. JPMorgan Chase & Co. dropped their target price on Kenvue from $24.00 to $21.00 and set an “overweight” rating on the stock in a report on Friday, October 10th. Bank of America lowered their price objective on Kenvue from $25.00 to $21.00 and set a “buy” rating on the stock in a research report on Wednesday, October 8th. Deutsche Bank Aktiengesellschaft set a $18.00 target price on shares of Kenvue in a report on Friday, October 24th. Zacks Research upgraded shares of Kenvue from a “strong sell” rating to a “hold” rating in a research note on Wednesday, November 26th. Finally, Citigroup lowered their price target on shares of Kenvue from $20.00 to $17.00 and set a “neutral” rating on the stock in a report on Thursday, October 9th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and thirteen have given a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $19.90.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.